Movement Disorders
Focus and Aim
The focus is on disorders in which the LUMC can make a significant contribution towards trial readiness of specific patient groups, including the establishment of patient registries, and development of meaningful outcome measures in one or more domains of the bio-psycho-social context. Additionally, to improve existing therapies and to develop innovative treatments, which is done in close collaboration with our basic science research partners.
…Focus and Aim
The focus is on disorders in which the LUMC can make a significant contribution towards trial readiness of specific patient groups, including the establishment of patient registries, and development of meaningful outcome measures in one or more domains of the bio-psycho-social context. Additionally, to improve existing therapies and to develop innovative treatments, which is done in close collaboration with our basic science research partners.
Expert Centers
Huntington’s disease (HD)
The Leiden HD center is one of the largest clinical centers for Huntington Disease in Europe and participates in multiple national and international, investigator-initiated (e.g. EHDN seed fund, HEALTHE-RND), CHDI funded (Enroll-HD with > 500 participants), IMI and EFPIA funded (e.g. IDEA-FAST), and industry-initiated clinical trials. Patients can opt to participate in research studies, clinical trials or several biobank initiatives, like the LUMC Biobank. We actively pursue partnership with stakeholders, such as patient organizations, regulators and pharmaceutical companies
…Huntington’s disease (HD)
The Leiden HD center is one of the largest clinical centers for Huntington Disease in Europe and participates in multiple national and international, investigator-initiated (e.g. EHDN seed fund, HEALTHE-RND), CHDI funded (Enroll-HD with > 500 participants), IMI and EFPIA funded (e.g. IDEA-FAST), and industry-initiated clinical trials. Patients can opt to participate in research studies, clinical trials or several biobank initiatives, like the LUMC Biobank. We actively pursue partnership with stakeholders, such as patient organizations, regulators and pharmaceutical companies
Parkinson’s disease (PD)
The centre for Parkinson’s disease in the LUMC is a tertiary referral centre with a longstanding track-record in care and research in PD. Together with the DBS team of the HagaZiekenhuis we are the second-largest DBS centre in The Netherlands, with more than 450 surgeries performed in 2022.
The research group focuses on an observational, multicenter, longitudinal study (Profiling Parkinson’s disease) to evaluate the role of existing and novel quantitative biomarkers in understanding the heterogeneity in the Parkinson’s phenotype and predicting treatment response as well as the occurrence of adverse drug responses, Deep brain stimulation and Host – microbiome interactions in PD and rremote monitoring technologies for digital phenotyping PD.